Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
ARGX-101
- Development stage
- Preclinical
- Lead developer
- Tensegrity Pharma
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
01
Overview
ARGX-101 (also known as TSP-101) is a preclinical-stage monoclonal antibody developed by argenx that targets the fibroblast growth factor-inducible 14 (Fn14) receptor, a member of the tumor necrosis factor receptor superfamily (TNFRSF12A). Fn14 is the sole signaling receptor for the cytokine TWEAK (TNF-like weak inducer of apoptosis). The TWEAK/Fn14 axis is a key regulator of tissue remodeling and inflammation, and its overactivation is linked to chronic inflammatory diseases, fibrosis, and the progression of various solid tumors. ARGX-101 is designed to bind Fn14 and block its interaction with TWEAK, thereby inhibiting downstream pro-inflammatory and pro-survival signaling pathways. The program was the first to emerge from argenx's Target Seed Program (TSP) but is not currently listed in the company's active clinical pipeline, indicating it is either in early development or a legacy asset.
- Other names
- anti-Fn14 monoclonal antibodyanti-Fn-14 monoclonal antibodyanti-Fn 14 monoclonal antibody
02
Targets
TNFRSF12A (Tumor necrosis factor-like weak inducer of apoptosis receptor)
Beyond the preview
Go deeper on ARGX-101.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ARGX-101.